Evaluation of 177Lu-Labeled Pertuzumab F(ab′)2 Fragments for HER2-Positive Cancer Targeting: A Comparative In Vitro and In Vivo Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of ¹⁷⁷Lu-Labeled Pertuzumab F(ab′)₂ Fragments for HER2-Positive Cancer Targeting: A Comparative In Vitro and In Vivo Study

Published:2024-02-01 Issue:1 Volume:39 Page:64-74
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Sharma Rohit¹²,Mukherjee Archana¹²^ORCID,Kumar Anuj¹,Sarma Haladhar Dev³

Affiliation:

1. Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India.

2. Department of Life Sciences, Homi Bhabha National Institute, Mumbai, India.

3. Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre (BARC), Mumbai, India.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2023.0108

Reference42 articles.

1. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

2. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

3. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12–21.32

4. The Human Epidermal Growth Factor Receptor 2 (HER2) as a Prognostic and Predictive Biomarker: Molecular Insights into HER2 Activation and Diagnostic Implications

5. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP